Prolonged PFS With Obinutuzumab in Advanced FL, Regardless of Chemo Backbone

AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news